Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 145,208 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder Clear all
Completed Phase 2 Interventional Results available

Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy

NCT02913482
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Month to 7 Months
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Palo Alto, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Nov 1, 2026, 9:38 AM EST
Recruiting Phase 2 Interventional

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

NCT05672524
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma, Rectal Cancer
Interventions
Trastuzumab, Tucatinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed No phase listed Observational Results available

Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application

NCT01922024
View directory record Official record
Conditions
Pneumonia
Interventions
LRT55 Testing
Device
Lead sponsor
Curetis GmbH
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Nov 1, 2026, 9:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

African-American Bone Metabolism and Lactation Study

NCT00785824
View directory record Official record
Conditions
Lactation, Bone Diseases, Endocrine
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Nov 1, 2026, 9:38 AM EST
Completed No phase listed Observational

The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome

NCT01754324
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Methadone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 1 Month
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)

NCT04575324
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Telemedicine Linkage Intervention
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Nov 1, 2026, 9:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

NCT04856124
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Intranasal esketamine
Drug
Lead sponsor
Psych Atlanta
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Nov 1, 2026, 9:38 AM EST
Active, not recruiting Phase 2 Interventional

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Plainville, Connecticut • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Nov 1, 2026, 9:38 AM EST
Not listed Not applicable Interventional

Study of an Intervention to Improve Problem List Accuracy and Use

NCT01105923
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 2 Interventional Results available

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

NCT02572323
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Tesamorelin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

NCT04909723
View directory record Official record
Conditions
Healthy Volunteers, Enteric Hyperoxaluria
Interventions
NOV-001, NB1000S, NB2000P, Placebo
Combination Product · Biological · Drug
Lead sponsor
Novome Biotechnologies Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

NCT00738023
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Rosiglitazone, Normal saline 0.9%, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Nov 1, 2026, 9:38 AM EST
Withdrawn No phase listed Observational Accepts healthy volunteers

TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH

NCT04280523
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ESR-specific PET scan
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

NCT02626338
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Interventions
Crenolanib, Mitoxantrone, Cytarabine, Etoposide, Fludarabine, G-CSF, Idarubicin
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Little Rock, Arkansas • Duarte, California • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Nov 1, 2026, 9:38 AM EST
Active, not recruiting Not applicable Interventional

Improving the Part C Early Intervention Service Delivery System for Children With ASD

NCT05114538
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Reciprocal Imitation Training
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
16 Months to 33 Months
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • East Lansing, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 1 Interventional

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

NCT00526838
View directory record Official record
Conditions
Cancer, Lymphoma
Interventions
XL228
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional Results available

Reducing Care-Resistant Behaviors During Oral Hygiene in Persons With Dementia

NCT01363258
View directory record Official record
Conditions
Care-resistant Behavior, Dementia
Interventions
Care-resistant mouth care (MOUTh), Evidence-based mouth care
Behavioral · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Bellefonte, Pennsylvania • Harrisburg, Pennsylvania • York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 2 Interventional Results available

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

NCT04524858
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndrome
Interventions
ATI-450
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 1, 2026, 9:38 AM EST
Enrolling by invitation No phase listed Observational

4T Sustainability Program

NCT06314048
View directory record Official record
Conditions
Type1diabetes
Interventions
CGM and RPM
Other
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 21 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 1 Interventional

Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia

NCT00575848
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Glycine, Placebo
Dietary Supplement
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Nov 1, 2026, 9:38 AM EST
Completed No phase listed Observational

Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event

NCT00241748
View directory record Official record
Conditions
Rhabdomyolysis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
30 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Nov 1, 2026, 9:38 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Novel Clinical Utility of Retinal Imaging in Patients With Heart Failure

NCT05086978
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 1, 2026, 9:38 AM EST